AcelRx Pharmaceuticals, Inc. (ACRX) Financial Statements (2024 and earlier)

Company Profile

Business Address 1850 GATEWAY DRIVE
SAN MATEO, CA 94404
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

9/30/2023
MRQ
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:20,77051,63042,88666,137105,71560,469
Cash and cash equivalents15,27512,66327,27414,68487,97552,902
Short-term investments 49538,96715,61251,45317,7407,567
Other undisclosed cash, cash equivalents, and short-term investments 5,000     
Receivables 3091606355204011,533
Inventory, net of allowances, customer advances and progress billings 1,1781,1111,6263,295854956
Inventory 1,1781,1111,6263,295854956
Disposal group, including discontinued operation      
Other undisclosed current assets2,3092,5881,6831,7361,024455
Total current assets:24,56655,48946,83071,688107,99463,413
Noncurrent Assets
Operating lease, right-of-use asset 3,5954,3023,1503,928
Nontrade receivables    263351 
Property, plant and equipment 10,26115,92815,65914,55211,48311,051
Intangible assets, net (including goodwill)8,819     
Intangible assets, net (excluding goodwill)8,819     
Restricted cash and investments     178178
Other noncurrent assets2462,174656925527207
Deferred tax assets, net 703
Total noncurrent assets:22,92122,40419,46519,66812,53912,139
TOTAL ASSETS:47,48777,89366,29591,356120,53375,552
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities6,3068,6457,6277,2486,6104,967
Accounts payable2,0402,1212,7371,7202,0701,424
Accrued liabilities4,2666,5244,8905,5284,5403,543
Deferred revenue   49300
Debt 5,7638,7968,7355,6008,6117,727
Disposal group, including discontinued operation      
Deferred revenue and credits362
Other undisclosed current liabilities 1,7011,0681,224463707604
Total current liabilities:13,77018,50917,63513,61115,92813,660
Noncurrent Liabilities
Long-term debt and lease obligation  8,75715,74624,1573,38011,369
Long-term debt, excluding current maturities  5,00713,14020,5173,38011,369
Liabilities, other than long-term debt 4,8051,2322993,5904163,841
Deferred revenue and credits3,841
Deferred revenue 1,0361,151 3,100
Deferred rent credit     416
Other liabilities 81081299490  
Operating lease, liability 2,9593,7502,6063,640
Other undisclosed noncurrent liabilities7,09885,28888,36591,41696,55683,191
Total noncurrent liabilities:11,90395,277104,410119,163100,35298,401
Total liabilities:25,673113,786122,045132,774116,280112,061
Equity
Equity, attributable to parent21,814(35,893)(55,750)(41,418)4,253(36,509)
Common stock813798797851
Additional paid in capital447,635437,554382,637356,609349,194261,310
Accumulated deficit(425,829)(473,584)(438,485)(398,106)(345,019)(297,870)
Total equity:21,814(35,893)(55,750)(41,418)4,253(36,509)
TOTAL LIABILITIES AND EQUITY:47,48777,89366,29591,356120,53375,552

Income Statement (P&L) ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Revenues1,7712,8185,4162,2892,1517,995
Sublease income  199598596
Cost of revenue(2,591)(4,275)(6,032)(6,806)(3,976)(369)
Cost of goods and services sold(2,591)(3,753)(6,032)(6,806)(3,976)(369)
Gross profit:(820)(1,457)(616)(4,517)(1,825)7,626
Operating expenses(35,813)(34,508)(40,347)(49,688)(37,878)(46,677)
Other undisclosed operating income     3,976369
Operating loss:(36,633)(35,965)(40,963)(54,205)(35,727)(38,682)
Nonoperating income (expense)84,401871588968(11,420)(13,527)
Investment income, nonoperating3661245832,1661,138510
Interest and debt expense(1,153)(2,291)(3,305)(2,535)(2,217)(3,316)
Income (loss) from continuing operations before equity method investments, income taxes:46,615(37,385)(43,680)(55,772)(49,364)(55,525)
Other undisclosed income from continuing operations before income taxes1,1532,2913,3052,5352,2173,316
Income (loss) from continuing operations before income taxes:47,768(35,094)(40,375)(53,237)(47,147)(52,209)
Income tax expense (benefit)(13)(5)(4)(3)(2)701
Income (loss) from continuing operations:47,755(35,099)(40,379)(53,240)(47,149)(51,508)
Loss before gain (loss) on sale of properties:(35,099)(40,379)(53,240)(47,149)(51,508)
Net income (loss):47,755(35,099)(40,379)(53,240)(47,149)(51,508)
Other undisclosed net loss attributable to parent      
Net income (loss) attributable to parent:47,755(35,099)(40,379)(53,240)(47,149)(51,508)
Preferred stock dividends and other adjustments (186)     
Undistributed earnings (loss) allocated to participating securities, basic(5,240)     
Net income (loss) available to common stockholders, basic:42,329(35,099)(40,379)(53,240)(47,149)(51,508)
Other undisclosed net income available to common stockholders, diluted13     
Net income (loss) available to common stockholders, diluted:42,342(35,099)(40,379)(53,240)(47,149)(51,508)

Comprehensive Income ($ in thousands)

9/30/2023
TTM
12/31/2022
12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net income (loss):47,755(35,099)(40,379)(53,240)(47,149)(51,508)
Comprehensive income (loss):47,755(35,099)(40,379)(53,240)(47,149)(51,508)
Other undisclosed comprehensive loss, net of tax, attributable to parent      (3)
Comprehensive income (loss), net of tax, attributable to parent:47,755(35,099)(40,379)(53,240)(47,149)(51,511)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: